FDA-cleared profile

QFR (3.0)

QFR Solutions bv · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.

Clinical role
Post-processing decision support for quantitative coronary vessel and lesion assessment and pressure-drop estimation; it supplements, rather than replaces, angiographic and clinical judgment.
Images and patients
Fluoroscopy/Angiography · Heart/Cardiovascular
Key limitation
Keep in mind: The analysis requires suitable paired angiographic views, calibration, at least five frames, and adequate vessel visibility. The user must review and correct contours or reference diameter when needed; incorrect contours or reference diameter can produce an incorrect QFR result. The output is not a replacement for clinical judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Heart/Cardiovascular Input: Coronary X-ray angiography DICOM acquisitions from a monoplane or biplane system, with two suitable projections separated by at least 25 degrees and adequate calibration and image quality.
  • Who uses it?Intended users: Interventional cardiologists or researchers who review coronary angiography; responsible clinicians must review and may correct analysis inputs and contours.
  • What does the software produce?Output: Three-dimensional reconstructed coronary vessels, vessel and lesion dimensions, quantitative flow ratio/pressure-drop values, analysis snapshots, and a report containing patient, acquisition, and analysis information.
  • What is its most important limitation?Key limitation: The analysis requires suitable paired angiographic views, calibration, at least five frames, and adequate vessel visibility. The user must review and correct contours or reference diameter when needed; incorrect contours or reference diameter can produce an incorrect QFR result. The output is not a replacement for clinical judgment.

Clinical takeaway. Clinical role: QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.

Evidence takeaway. Evidence from the reviewed source record: K243769 FDA evidence is a regulatory image-analysis validation for QFR 3.0; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Post-processing decision support for quantitative coronary vessel and lesion assessment and pressure-drop estimation; it supplements, rather than replaces, angiographic and clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Coronary X-ray angiography DICOM acquisitions from a monoplane or biplane system, with two suitable projections separated by at least 25 degrees and adequate calibration and image quality.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Three-dimensional reconstructed coronary vessels, vessel and lesion dimensions, quantitative flow ratio/pressure-drop values, analysis snapshots, and a report containing patient, acquisition, and analysis information.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Cardiac catheterization laboratory or image-review workstation supporting coronary angiography analysis.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Interventional cardiologists or researchers who review coronary angiography; responsible clinicians must review and may correct analysis inputs and contours.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The analysis requires suitable paired angiographic views, calibration, at least five frames, and adequate vessel visibility. The user must review and correct contours or reference diameter when needed; incorrect contours or reference diameter can produce an incorrect QFR result. The output is not a replacement for clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243769 FDA evidence is a regulatory image-analysis validation for QFR 3.0; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243769 FDA evidence is a regulatory image-analysis validation for QFR 3.0; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

RCA vessel classification correct

96 percent

  • EndpointCorrect vessel classification for RCA
  • PopulationRegulatory QFR image-analysis validation cases
  • Tested versionQFR 3.0 configuration described in K243769

LAD vessel classification correct

88 percent

  • EndpointCorrect vessel classification for LAD
  • PopulationRegulatory QFR image-analysis validation cases
  • Tested versionQFR 3.0 configuration described in K243769

LCX vessel classification correct

78 percent

  • EndpointCorrect vessel classification for LCX
  • PopulationRegulatory QFR image-analysis validation cases
  • Tested versionQFR 3.0 configuration described in K243769

Start/end detection correct

77 percent

  • EndpointCorrect automatic start and end point detection
  • PopulationRegulatory QFR image-analysis validation cases
  • Tested versionQFR 3.0 configuration described in K243769

K243769 QFR 3.0 regulatory image-analysis validation

  • DesignRetrospective regulatory validation of vessel classification, endpoint detection, and QFR image-analysis outputs on coronary X-ray angiography.
  • PopulationCoronary angiography studies representative of intended interventional cardiology or research use; the reviewed FDA summary reports endpoint percentages without a single overall sample count.
  • Scopeexact submission
  • Tested versionQFR 3.0 configuration described in K243769
  • IndependenceSponsor or vendor study

K243769

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K243769. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Coronary X-ray angiography DICOM acquisitions from a monoplane or biplane system, with two suitable projections separated by at least 25 degrees and adequate calibration and image quality.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243769: QFR (3.0)

  2. Routing

    Source context, not route validation: The exact software imports coronary XA DICOM studies and can exchange studies and reports with PACS through DICOM services; local modality, PACS, worklist, export, and report routing require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243769: QFR (3.0)

  3. AI processing

    Source context, not route validation: The exact FDA packet and QFR manual describe a server installed in the organization network or cathlab/hospital server room, accessed through a web browser; the manual states the QFR server is not cloud or internet hosted for the reviewed version.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243769: QFR (3.0) · QFR 3.0 User Manual, FDA version

  4. Returned objects

    Source context, not route validation: Three-dimensional reconstructed coronary vessels, vessel and lesion dimensions, quantitative flow ratio/pressure-drop values, analysis snapshots, and a report containing patient, acquisition, and analysis information.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243769: QFR (3.0)

  5. Viewer/worklist/report

    Unresolved route: Three-dimensional reconstructed coronary vessels, vessel and lesion dimensions, quantitative flow ratio/pressure-drop values, analysis snapshots, and a report containing patient, acquisition, and analysis information.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243769: QFR (3.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA packet and QFR manual describe a server installed in the organization network or cathlab/hospital server room, accessed through a web browser; the manual states the QFR server is not cloud or internet hosted for the reviewed version.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact software imports coronary XA DICOM studies and can exchange studies and reports with PACS through DICOM services; local modality, PACS, worklist, export, and report routing require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Training
Use requires trained interventional cardiologist or researcher review of projection selection, calibration, vessel and lesion contours, reference diameter, QFR result, and report; local competency and escalation procedures remain site responsibilities.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor projection and calibration eligibility, contour edits, completed versus no-result analyses, report and DICOM delivery, reader overrides, user/audit events, downtime, updates, complaints, and recalls by exact K243769 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and manual; it is not a claimed vendor monitoring service.

Local server deployment

The QFR manual places the QFR server in the organization network and states it is not cloud or internet hosted for the reviewed version; access is through a web browser and local DICOM connections must be configured.

product family · checked 2026-09-07

Manual version 3.0.36.6 was reviewed; confirm that the installed K243769 release has the same deployment behavior.

DICOM and report workflow

The manual documents DICOM connection administration, PACS export, audit trail, user roles, and report archiving when configured; test modality import, projection selection, export, report delivery, and failure recovery locally.

product family · checked 2026-09-07

Input-quality gate

The reviewed manual requires XA studies with grayscale square pixels, fixed angulation, calibration, at least five frames, and two projections with at least 25 degrees between angles; invalid or incomplete acquisitions may block or distort analysis.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243769
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K243769 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "QFR Solutions reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed packet and manual describe local deployment, user roles, and audit-trail functions but do not establish a current scoped security attestation, encryption configuration, retention, vulnerability management, or incident response for the installed K243769 release.

  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243769: QFR (3.0)

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. QFR (3.0) model card (K243769)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. QFR 3.0 User Manual, FDA version

    QFR Solutions / Medis Medical Imaging Systems - Accessed 2026-09-07

    Scope: productFamily, implementationCapabilities, limitations

  8. openFDA exact recall query for K243769

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K243769 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252500

CARA System

Cara Medical, Ltd.

Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20
FDA-cleared K243884

TAVIPILOT

Caranx Medical

Authorized purpose: TAVIPILOT detects, tracks, and marks the non-coronary cusp and prosthetic valve on live fluoroscopy during specified adult femoral TAVR or TAVI procedures under physician control.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2025-07-07
FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history